“Prime Minster Shri. Narendra Modi’s visit to Bharat Biotech today was a momentous occasion.” mentioned a statement from Bharat Biotech. “We are humbled by the visit of Shri. Narendra Modi Ji to the Bharat Biotech manufacturing facility in Genome Valley, Hyderabad.”
The prime minister’s visit serves as a great inspiration to our team, and further reinforces our commitment towards scientific discovery, solving public health issues, and the nation’s fight against COVID-19.
COVAXIN™ is India’s first indigenous vaccine with a phase-3 clinical trial underway. It is the first, largest, and only efficacy trial in the developing world, involving a large number of volunteers across 25 sites.
Covaxin India’s Universal Vaccine
The COVAXIN™ phase-3 trial is being conducted across India with 26,000 participants. The vaccine will be produced in the only-of-its-kind Biosafety Level 3 (BSL 3) production facility in the world.
“We take this opportunity to thank the Government of India, regulators, our vaccine development partners, medical fraternity, medical investigators, including hospitals, for their relentless assistance and cooperation in the development of vaccines, also phase-3 clinical trials for COVAXIN™.” mentioned a representative from Bharat Biotech.
“We greatly appreciate every volunteer who has come forward for the trial thus far and we thank you for your service to the nation. Bharat Biotech reiterates our commitment towards developing a safe and efficacious vaccine for all.” added the representative.